AnteoTech (ASX:ADO) share price soars 7% on news of rapid COVID-19 test

Shares in the biotech company are gaining today following an update on its rapid diagnostic test

| More on:
Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The AnteoTech Ltd (ASX: ADO) share price is rocketing today. This comes after news the company has submitted its SARS-CoV-2 antigen rapid diagnostic test for Therapeutic Goods Administration (TGA) approval.

According to the company, its rapid diagnostic test is able to detect COVID-19 in 97.3% of cases and can provide results in 1 minute.  

At the time of writing, the AnteoTech share price is 29.5 cents, 7.27% higher than its previous close.

Let's take a closer look at today's news from the biotechnology company.

Rapid COVID-19 test submitted for TGA approval

The AnteoTech share price is soaring after the company announced it has submitted its COVID-19 rapid diagnostic test for TGA approval.

AnteoTech's test uses a nasal swap to test for COVID-19 infections in 1 minute. AnteoTech is also working on creating a saliva-based sampling method.

The test has been submitted for TGA approval alongside AnteoTech's Eugeni Reader Platform – a transportable device needed to read AnteoTech's rapid COVID-19 tests.

If the products receive TGA approval, AnteoTech will begin marketing, selling, and using the tests in Australia.

AnteoTech is already working with Australian distributor, Abacus dx, in the hope the rapid testing products will be approved.

Abacus has a strong pipeline of potential customers for the test across the healthcare and screening markets. AnteoTech believes the test's first sales will happen shortly after it's listed on the Australian Register of Therapeutic Goods.

The AnteoTech share price soared 14% last week when the company announced a distribution agreement to sell the rapid tests in Greece and Cyprus.

Additionally, if the TGA grants approval for the rapid test, it will create a benchmark for its efficacy and quality.

Currently, numerous COVID-19 rapid diagnostic tests are approved for use in Australia.

However, the TGA advises rapid diagnostic tests for COVID-19 shouldn't be relied upon. The body says the prevalence of COVID-19 in Australia is lower than the number of false positives or false negatives that would likely result from rapid testing.

AnteoTech share price snapshot

Today's gains included, the AnteoTech share price is 168% higher than it was at the start of 2021.

It has also gained 268% since this time last year.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Up 680% since July, here's why 2025 was a breakout year for this hot ASX stock

With consistent contract wins, FDA clearance, and backing from Pro Medicus, 4D Medical is showing that there is a commercial…

Read more »

Shot of a senior scientist looking stressed out while working in a lab.
Healthcare Shares

After soaring 40% in 2 weeks, this ASX All Ords healthcare stock has been downgraded

Here’s what analysts at Macquarie rate the stock as now.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Own NIB shares? Here are the key dates for 2026

NIB has released its corporate calendar, including dividend dates, for 2026.

Read more »

A male doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused
Healthcare Shares

ASX healthcare stock debuts at a massive discount to its initial public offer price

Saluda Medical shares have had a difficult start to public life, trading well below the initial public offer price.

Read more »

Red buy button on an apple keyboard with a finger on it representing asx tech shares to buy today
Healthcare Shares

Why CSL shares now look 'massively oversold'

A leading investment expert says ASX investors have a rare chance to buy CSL shares at a discount.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Which junior biotech's shares are flying on positive trial news?

This company's shares have surged higher after positive clinical trial results for its stroke treatment drug.

Read more »

Excited elderly woman on a swing.
Healthcare Shares

Guess which ASX 300 healthcare share is lifting off on $25 million news

The ASX 300 healthcare share is grabbing investor interest on Thursday. Let’s see why.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Doomed takeover bid for Mayne Pharma to come to an end

The Mayne Pharma takeover saga appears to be finally drawing to an end, with shareholders bearing the pain of the…

Read more »